Wharton's Jelly Mesenchymal Stem Cells as Candidates for Beta Cells Regeneration: Extending the Differentiative and Immunomodulatory Benefits of Adult Mesenchymal Stem Cells for the Treatment of Type 1 Diabetes

Stem Cell Reviews and Reports

Volumn 7, Issue 2, 2011, Pages 342-363

  Anzalone, Rita ^a   Iacono, Melania Lo ^a   Loria, Tiziana ^a   Stefano, Antonino Di ^b   Giannuzzi, Pantaleo ^b   Farina, Felicia ^a   la Rocca, Giampiero ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b IRCCS   (Italy)

Author keywords

Beta cells; Differentiation markers; Hypoimmunogenicity; Immune modulation; Inflammation; Mesenchymal stem cells; Pancreas development; Type 1 diabetes; Umbilical cord; Wharton's jelly

Indexed keywords

DIFFERENTIATION ANTIGEN;

ADIPOSE TISSUE; ADULT STEM CELL; ANIMAL; CELL DIFFERENTIATION; CORD BLOOD STEM CELL TRANSPLANTATION; CULTURE TECHNIQUE; CYTOLOGY; EMBRYONIC STEM CELL; GRAFT REJECTION; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PANCREAS ISLET BETA CELL; PHYSIOLOGY; REGENERATION; REVIEW; TRANSPLANTATION; UMBILICAL CORD;

ADIPOSE TISSUE; ADULT STEM CELLS; ANIMALS; ANTIGENS, DIFFERENTIATION; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CORD BLOOD STEM CELL TRANSPLANTATION; DIABETES MELLITUS, TYPE 1; EMBRYONIC STEM CELLS; GRAFT REJECTION; HUMANS; IMMUNOMODULATION; INSULIN-SECRETING CELLS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; REGENERATION; UMBILICAL CORD;

EID: 79954994410     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-010-9196-4     Document Type: Review

References (164)

1. Friedenstein, A. J., Gorskaya, J. F., & Kulagina, N. N. (1976). Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Experimental Hematology, 4, 267-274.
2. Caplan, A. I. (1991). Mesenchymal stem cells. Journal of Orthopaedic Research, 9, 641-650.
3. Horwitz, E. M., Le Blanc, K., Dominici, M., et al. (2005). Clarification of the nomenclature for MSC: the international society for cellular therapy position statement. Cytotherapy, 7, 393-395.
4. Secco, M., Moreira, Y. B., Zucconi, E., et al. (2009). Gene expression profile of mesenchymal stem cells from paired umbilical cord units: cord is different from blood. Stem Cell Reviews and Reports, 5, 387-401.
5. Anzalone, R., Lo Iacono, M., Corrao, S., et al. (2010). New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. Stem Cells and Development, 19, 423-438.
6. Hung, S. C., Chen, N. J., Hsieh, S. L., Ma, H. L., & Lo, W. H. (2002). Isolation and characterization of size-sieved stem cells from human bone marrow. Stem Cells, 20, 249-258.
7. Delorme, B., Ringe, J., Gallay, N., et al. (2008). Specific plasma membrane protein phenotype of cultureamplified and native human bone marrow mesenchymal stem cells. Blood, 111, 2631-2635.
8. Reger, R. L., Tucker, A. H., & Wolfe, M. R. (2008). Differentiation and characterization of human MSCs. Methods in Molecular Biology, 449, 93-107.
9. Turnovcova, K., Ruzickova, K., Vanecek, V., Sykova, E., & Jendelova, P. (2009). Properties and growth of human bone marrow mesenchymal stromal cells cultivated in different media. Cytotherapy, 11, 874-885.
10. Weiss, M. L., Medicetty, S., Bledsoe, A. R., et al. (2006). Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells, 24, 781-792.
11. Rao, M. S., & Mattson, M. P. (2001). Stem cells and aging: expanding the possibilities. Mechanisms of Ageing and Development, 122, 713-734.
12. Romanov, Y. A., Svintsitskaya, V. A., & Smirnov, V. N. (2003). Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like from umbilical cord. Stem Cells, 21, 105-110.
13. La Rocca, G., Anzalone, R., Corrao, S., et al. (2009). Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Histochemistry and Cell Biology, 131, 267-282.
14. Majore, I., Moretti, P., Stahl, F., Hass, R., & Kasper, C. (2010). Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord. Stem Cell Reviews and Reports. doi: 10. 1007/s12015-010-9165-y.
15. Fong, C. Y., Chak, L. L., Biswas, A., et al. (2010). Human Wharton's jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells. Stem Cell Reviews and Reports. doi: 10. 1007/s12015-010-9166-x.
16. La Rocca, G., Anzalone, R., & Farina, F. (2009). The expression of CD68 in human umbilical cord mesenchymal stem cells: new evidences of presence in non-myeloid cell types. Scandinavian Journal of Immunology, 70, 161-162.
17. Weiss, M. L., Anderson, C., Medicetty, S., et al. (2008). Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells, 26, 2865-2874.
18. Vija, L., Fargec, D., Gautier, J. F., et al. (2009). Mesenchymal stem cells: stem cell therapy perspectives for type 1 diabetes. Diabetes & Metabolism, 35, 85-93.
19. Di Nicola, M., Carlo-Stella, C., Magni, M., et al. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99, 3838-3843.
20. Li, D. S., Warnock, G. L., Tu, H. J., et al. (2009). Do immunotherapy and β cell replacement play a sinergistic role in the treatment of type 1 diabetes? Life Sciences, 85, 549-556.
21. Nichols, J., & Cooke, A. (2009). Overcoming self-destruction in pancreas. Current Opinion in Biotechnology, 20, 511-515.
22. Alma, J., Nauta, W., & Fibbe, E. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood, 110, 3499-3506.
23. Selmani, Z., Naji, A., Gaiffe, E., et al. (2009). HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation, 87(9 Suppl.), S62-S66.
24. Le Bouteiller, P. (2000). HLA-G in the human placenta: expression and potential functions. Biochemical Society Transactions, 28, 208-212.
25. Ren, G., Zhao, X., Zhang, L., et al. (2010). Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cella adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. Journal of Immunology, 184, 2321-2328.
26. Krampera, M., Glennie, S., Dyson, J., et al. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 101, 3722-3729.
27. Djouad, F., Plence, P., Bony, C., et al. (2003). Immunosuppressive effect of mesenchymal stem cells favors tumour growth in allogeneic animals. Blood, 102, 3837-3844.
28. Aggarwal, S., & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105, 1815-1818.
29. Corcione, A., Benvenuto, F., Ferretti, E., et al. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood, 107, 367-372.
30. Németh, K., Leelahavanichkul, A., Yuen, P. S. T., et al. (2009). Bone marroew stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nature Medicine, 15, 42-49.
31. Mei, S. H., Haitsma, J. J., Dos Santos, C. C., et al. (2010). Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. American Journal of Respiratory and Critical Care Medicine. doi: 10. 1164/rccm. 201001-0010OC.
32. Barbagallo, I., Tibullo, D., Di Rosa, M., et al. (2008). A cytoprotective role for the heme oxygenase-1/CO pathway during neural differentiation of human mesenchymal stem cells. Journal of Neuroscience Research, 86, 1927-1935.
33. Jiang, Y., Chen, L., Tang, Y., et al. (2010). HO-1 gene overexpression enhances the beneficial effects of superparamagnetic iron oxide labeled bone marrow stromal cells transplantation in swine hearts underwent ischemia/reperfusion: a MRI study. Basic Research in Cardiology, 105, 431-442.
34. Tu, Z., Li, Q., Bu, H., & Lin, F. (2010). Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells and Development. doi: 10. 1089/scd. 2009. 0418.
35. Sato, K., Ozaki, K., Oh, I., et al. (2007). Nitric oxide plays a crucial role in suppression of T-cell proliferation by mesenchymal stem cells. Blood, 109, 228-234.
36. Ren, G., Zhang, L., Zhao, X., et al. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2, 141-150.
37. Yoo, K. H., Jang, I. K., Lee, M. W., et al. (2009). Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cellular Immunology, 259, 150-156.
38. Troyer, D. L., & Weiss, M. L. (2007). Concise review: Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells, 26, 591-599.
39. Wang, H. S., Hung, S. C., Peng, S. T., et al. (2004). Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells, 22, 1330-1337.
40. Götherstrom, C., West, A., Liden, J., Uzunel, M., Lahesmaa, R., & Le Blanc, K. (2005). Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells. Haematologica, 90, 1017-1026.
41. Selmani, Z., Naji, A., Zidi, I., Favier, B., et al. (2008). Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells, 26, 212-222.
42. Deans, R. J., & Moseley, A. B. (2000). Mesenchymal stem cells: biology and potential clinical uses. Experimental Hematology, 28, 875-884.
43. Xu, W., Zhang, X., Qian, H., et al. (2004). Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Experimental Biology and Medicine, 229, 623-631.
44. Sheng, H., Wang, Y., Jin, Y., et al. (2008). A critical role of IFNγ in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Research, 18, 846-857.
45. Xue, Q., Luan, X. Y., Gu, Y. Z., et al. (2010). The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity. Stem Cells and Development, 19, 27-38.
46. Friedman, R., Betancur, M., Boissel, L., Tuncer, H., Cetrulo, C., & Klingemann, H. (2007). Umbilical cord mesenchymal stem cells: adjuvants for human cell transplantation. Biology of Blood and Marrow Transplantation, 13, 1477-1486.
47. Guo, Z., Zheng, C., Chen, Z., et al. (2009). Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells. European Journal of Immunology, 39, 2840-2849.
48. Prasanna, S. J., Gopalakrishnan, D., Shankar, S. R., & Vasandan, A. B. (2010). Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One, 5, e9016.
49. Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevaxis, C. N., & Papamichail, M. (2006). Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells, 24, 74-85.
50. Zanone, M. M., Favaro, E., Miceli, I., et al. (2010). Human mesenchymal stem cells modulate cellular immune responses to islet antigen glutamic acid decarboxylase in type 1 diabetes. Journal of Clinical Endocrinology and Metabolism, 95, 3788-3797.
51. Chen, K., Wang, D., Du, W. T., et al. (2010). Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clinical Immunology, 135, 448-456.
52. Lee, R. H., Pulin, A. A., Seo, M. J., et al. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolie in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell, 5, 54-63.
53. Kadri, T., Lataillade, J. J., Doucet, C., et al. (2005). Proteomic study of galectin-1 expression in human mesenchymal stem cells. Stem Cells and Development, 14, 204-212.
54. Sioud, M., Mobergslien, A., Boudabous, A., & Fløisand, Y. (2010). Evidence for the involvement of galectin-3 in esenchymal stem cell suppression of allogeneic T-cell proliferation. Scandinavian Journal of Immunology, 71, 267-274.
55. Griffin, M. D., Ritter, T., & Mahon, B. P. (2010). Immunological aspects of allogeneic mesenchymal stem cell therapies. Human Gene Therapy. doi: 10. 1089/hum. 2010. 156.
56. Hunt, J. S., Petroff, M. G., McIntire, R. H., & Ober, C. (2005). HLA-G and immune tolerance in pregnancy. The FASEB Journal, 19, 681-693.
57. Corrao, S., Campanella, C., Anzalone, R., et al. (2010). Human Hsp10 and Early Pregnancy Factor (EPF) and their relationship and involvement in cancer and immunity: current knowledge and perspectives. Life Sciences, 86, 145-152.
58. Anzalone, R., La Rocca, G., Di Stefano, A., et al. (2009). Role of endothelial cell stress in the pathogenesis of chronic heart failure. Frontiers in Bioscience, 14, 2238-2247.
59. La Rocca, G., Di Stefano, A., Eleuteri, E., et al. (2009). Oxidative stress induces myeloperoxidase expression in endocardial endothelial cells from patients with chronic heart failure. Basic Research in Cardiology, 104, 307-320.
60. Eleuteri, E., Magno, F., Gnemmi, I., et al. (2009). Role of oxidative and nitro sative stress biomarkers in chronic heart failure. Frontiers in Biosciences, 14, 2230-2237.
61. Eleuteri, E., Di Stefano, A., Ricciardolo, F. L., et al. (2009). Increased nitrotyrosine plasma levels in relation to systemic markers of inflammation and myeloperoxidase in chronic heart failure. International Journal of Cardiology, 135, 386-390.
62. Dìaz-Lagares, A., Alegre, E., LeMaoult, J., Carosella, E. D., & Gonzalez, A. (2009). Nitric oxide produces HLA-G nitration and induces metalloprotease-dependent shedding creating a tolerogenic milieu. Immunology, 126, 436-445.
63. Gonzalez, M. A., Gonzalez-Rey, E., Rico, L., Büscher, D., & Delgado, M. (2009). Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis & Rheumatism, 60, 1006-1019.
64. Madec, A. M., Mallone, G., Alfonso, E., et al. (2009). Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia, 52, 1391-1399.
65. Zhao, Y., Lin, B., Darflinger, R., Zhang, Y., Holterman, M. J., & Skidgel, R. A. (2009). Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. PloS ONE, 4, e4226.
66. Sundin, M., Ringdén, O., Sundberg, B., Nava, S., Götherström, C., & Le Blanc, K. (2007). No alloantibodies against mesenchymal stem cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica, 92, 1208-1215.
67. Rasmusson, I., Uhlin, M., Le Blanc, K., & Levitski, V. (2007). Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. Journal of Leukocyte Biology, 82, 887-893.
68. Morandi, F., Raffaghello, L., Bianchi, G., et al. (2008). Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells, 26, 1275-1287.
69. Shabbir, A., Zisa, D., Leiker, M., Johnston, C., Lin, H., & Lee, T. (2009). Muscular dystrophy therapy by non-autologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammation. Transplantation, 87, 1275-1282.
70. Quevedo, H. C., Hatzistergos, K., Oskouei, B. N., et al. (2009). Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomiopathy via trilineage differentiating capacity. PNAS USA, 106, 14022-14027.
71. Chen, L., Tredget, E. E., Liu, C., & Wu, Y. (2009). Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice. PloS ONE, 4, e7119.
72. Eliopoulos, N., Stagg, J., Lejeune, L., Pommey, S., & Galipeau, J. (2005). Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood, 106, 4057-4065.
73. Nauta, A. J., Westerhuis, G., Kruisselbrink, A. B., Lurvink, E. G. A., Willemze, R., & Fibbe, W. E. (2006). Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood, 108, 2114-2120.
74. Prigozhina, T. B., Khitrin, S., Elkin, G., Eizik, O., Morecki, S., & Slavin, S. (2008). Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation. Experimental Hematology, 36, 1370-1376.
75. Chiavegato, A., Bollini, S., Pozzobon, M., et al. (2007). Human amniotic Xuid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immunosuppressed or immuno-deficient rat. Journal of Molecular and Cellular Cardiology, 42, 746-759.
76. Ren, G., Su, J., Zhang, L., et al. (2009). Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells, 27, 1954-1962.
77. Sudres, M., Norol, F., Trenado, A., et al. (2006). Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. Journal of Immunology, 176, 7761-7767.
78. Iyer, S. S., & Rojas, M. (2008). Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opinion in Biological Therapy, 8, 569-581.
79. Ringdén, O., Uzunel, M., Rasmusson, I., et al. (2006). Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation, 81, 1390-1397.
80. Zhang, X., Jiao, C., & Zhao, S. (2009). Role of mesenchymal stem cells in immunological rejection of organ transplantation. Stem Cell Reviews and Reports, 5, 402-409.
81. Ito, T., Itakura, S., Rawson, J., et al. (2010). Mesenchymal stem cell and islet co-transplantation promotes graft revascularizatioon and function. Transplantation, 89, 1438-1445.
82. Li, F. R., Wang, X. G., Deng, C. Y., Qi, H., Reb, L. L., & Zhou, H. X. (2010). Immune modulation of co-transplantation mesenchymal stem cells with islet on T and dendritic cells. Clinical and Experimental Immunology, 161, 357-363.
83. Longoni, B., Szilagyi, E., Quaranta, P., et al. (2010). Mesenchymal stem cells prevent acute rejection and prolong graft function in pancreatic islet transplantation. Diabetes Technology and Therapy, 12, 435-446.
84. Hoogduijn, M. J., Popp, F., Verbeek, R., et al. (2010). The immunotherapy properties of mesenchymal stem cells and their use for immunotherapy. International Immunopharmacology. doi: 10. 1016/j. intimp. 2010. 06. 019.
85. Popp, F. C., Eggenhofer, E., Renner, P., et al. (2008). Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transplant Immunology, 20, 55-60.
86. Ge, W., Jiang, J., Baroja, M. L., et al. (2009). Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. American Journal of Transplantation, 9, 1760-1772.
87. Le Blanc, K., Tammik, C., Rosendahl, K., Zettenberg, E., & Ringdén, O. (2003). HLA expression and immunogenic properties of differentiated and undifferentiated mesenchymal stem cells. Experimental Hematology, 31, 890-896.
88. Liu, H., Kemeny, D. M., Heng, B. C., Ouyang, H. W., Melendez, A. J., & Cao, T. (2006). The immunogenic and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. The Journal of Immunology, 176, 2864-2871.
89. Zheng, Z. H., Li, X. Y., Ding, J., Jia, J. F., & Zhu, P. (2008). Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology, 47, 22-30.
90. Chen, X., McClurg, A., Zhou, G. Q., McCaigue, M., Armstrong, M. A., & Li, G. (2007). Chondrogenic differentiation alters the immunosuppressive property of bone marrow-derived mesenchymal stem cells, and the effect is partially due to the upregulated expression of B7 molecules. Stem Cells, 25, 364-370.
91. Pittenger, M. (2009). Sleuthing the source of regeneration by MSCs. Cell Stem Cell, 5, 8-10.
92. Kemp, K., Gray, E., Mallam, E., Scolding, N., & Wilkins, A. (2010). Inflammatory cytokine induced regulation of superoxide dismutase 3 expression by human mesenchymal stem cells. Stem Cell Reviews and Reports. doi: 10. 1007/s12015-010-9178-6.
93. Liao, W., Zhong, J., Yu, J., et al. (2009). Therapeutic benefit of human umbilical cord derived mesenchymal stromal cells in intracerebral hemorrage rat: implication for anti-inflammation and angiogenesis. Cellular Physiology and Biochemistry., 24, 307-316.
94. Carreras, A., Almendros, I., Montserrat, J. M., Navajas, D., & Farré, R. (2010). Mesenchymal stem cells reduce inflammation in a rat model of obstructive sleep apnea. Respiratory Physiology & Neurobiology, 172, 210-212.
95. Cao, H., Quian, H., Xu, W., et al. (2010). Mesenchymal stem cells derived from human umbilical cord ameliorate ischemia/reperfusion-induced acute renal failure in rats. Biotechnology Letters, 32, 725-732.
96. Tsai, P. C., Fu, T. W., Chen, Y. M. A., et al. (2009). The therapeutic potential of human umbilical mesenchymal stem cells from Wharton's jelly in the treatment of rat liver fibrosis. Liver Transplantation, 15, 484-495.
97. Gonzalez, M. A., Gonzalez-Rey, E., Rico, L., Büscher, D., & Delgado, M. (2009). Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology, 136, 978-989.
98. Bonfield, T. L., Koloze, M. F., Lennon, D. P., Zuchowski, B., Yang, S. E., & Caplan, A. L. (2010). Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model. American Journal of Physiology Lung Cellular and Molecular Physiology. doi: 10. 1152/ajplung. 00182. 2009.
99. Ishikane, S., Yamahara, K., Sada, M., et al. (2010). Allogeneic administration of fetal membrane-derived mesenchymal stem cells attenuates acute myocarditis in rats. Journal of Molecular and Cellular Cardiology. doi: 10. 1016/j. yjmcc. 2010. 07. 019.
100. Kim, Y. S., Park, H. J., Hong, M. H., et al. (2009). TNF-alpha enhances engraftment of mesenchymal stem cells into infarcted myocardium. Frontiers in Bioscience, 14, 2845-2856.
101. Ende, N., Chen, R., & Reddi, A. S. (2004). Effect of human umbilical cord blood cells on glycemia and insulitis in type 1 diabetic mice. Biochemical and Biophysical Research Communications, 325, 665-669.
102. Wehling, N., Palmer, G. D., Pilapil, C., et al. (2009). Interleukin-1β and tumor necrosis factor α inhibit chondrogenesis by human mesenchymal stem cells through NF-κB-dependent pathways. Arthritis & Rheumatism, 60, 801-812.
103. Weir, G. C., & Bonner-Weir, S. (2010). Dreams for type 1 diabetes: shutting off autoimmunity and stimulating beta-cell regeneration. Endocrinology, 151, 2971-2973.
104. Dor, Y., & Stanger, B. Z. (2007). Regeneration in liver and pancreas: time to cut the umbilical cord? Science STKE, 414, pe66.
105. Eberhard, D., Lammert, E. (2009). The pancreatic β-cell in the islet and organ community. Current Opinion in Genetics & Development, 19, 469-475.
106. Sun, B., Roh, K. H., Lee, S. R., Lee, Y. S., Kang, K. S. (2007). Induction of human umbilical cord blood-derived stem cells with embryonic stem cell phenotypes into insulin producing islet- like structure. Biochemical and Biophysical Research Communications, 354, 919-923.
107. Wu, L. F., Wang, N. N., Liu, Y. S., Wei, X. (2009). Differentiation of Wharton's Jelly primitive stromal cells into insulin-producing cells in comparison with bone marrow mesenchymal stem cells. Tissue Engineering Part A, 15, 2865-2873.
108. MacDonald, M. R., Petrie, M. C., Hawkins, N. M., et al. (2008). Diabetes, left ventricular systolic dysfunction, and chronic heart failure. European Heart Journal, 29, 1224-1240.
109. Scrutinio, D., Giannuzzi, P. (2008). Comorbidity in patients undergoing coronary artery bypass graft surgery: impact on outcome and implications for cardiac rehabilitation. European Journal of Cardiovascular Prevention and Rehabilitation, 15, 379-385.
110. Palma, C. A., Lindeman, R., Tuch, B. E. (2008). Blood into β-cells: can adult stem cells be used as a therapy for type 1 diabetes? Regenerative Medicine, 3, 1-15.
111. Sahu, S., Tosh, D., Hardikar, A. A. (2009). New sources of β-cells for treating diabetes. Journal of Endocrinology, 202, 13-16.
112. Aguayo-Mazzuccato, C., & Bonner-Weir, S. (2010). Stem cell therapy for type 1 diabetes mellitus. Nature Reviews Endocrinology, 6, 139-148.
113. Fadini, G. P., Sartore, S., Schiavon, M., et al. (2006). Diabetes impairs progenitor cell mobilization after hindlimb hischaemia-reperfusion injury in rats. Diabetologia, 49, 3075-3084.
114. Gallagher, K. A., Liu, Z. J., Xiao, M., et al. (2007). Diabetic impaiorments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. Journal of Clinical Investigation, 117, 1249-1259.
115. McKnight, K. D., & Kim, S. K. (2010). Deconstructing pancreas development to reconstruct human islets from pluripotent stem cells. Cell Stem Cell, 6, 300-308.
116. Puri, S., & Hebrok, M. (2010). Cellular plasticity within the pancreas-lessons learned from development. Developmental Cell, 18, 342-356.
117. Guney, M. A., & Gannon, M. (2009). Pancreas cell fate. Birth Defects Research (Part C), 87, 232-248.
118. McDonald, E., Krishnamurthy, M., Goodyer, C. G., & Wang, R. (2009). The emerging roles of SOX transcription factors in pancreatic endocrine cell development and function. Stem Cells and Development, 18, 1379-1387.
119. Shao, S., Fang, Z., Yu, X., & Zhang, M. (2009). Transcription factors involved in glucose-stimulated insulin secretion of pancreatic beta cells. Biochemical and Biophysical Research Communications, 384, 401-404.
120. Burlison, J. S., Long, Q., Fujitani, Y., et al. (2008). Pdx-1 and Ptf1a concurrently determine the fate specification of pancreatic multipotent progenitor cells. Developmental Biology, 316, 74-86.
121. Kawaguchi, Y., Cooper, B., Gannon, M., et al. (2002). The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nature Genetics, 32, 128-134.
122. Sellick, G. S., Barker, K. T., Stolte-Dijkstra, I., et al. (2004). Mutations in Ptf1a cause pancreatic and cerebellar agenesis. Nature Genetics, 36, 1301-1305.
123. Gradwohl, G., Dierich, A., LeMeur, M., & Guillemot, F. (2000). Neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. Proceedings of the National Academy of Sciences USA, 97, 1607-1611.
124. Sussel, L., Kalamaras, J., Hartingan-O'Connor, D. J., et al. (1998). Mice lacking the homeodomain transcription factor Nkx2. 2 have diabetes due to arrested differentiation of pancreatic beta cells. Development, 125, 2213-2221.
125. Servitja, J. M., & Ferrer, J. (2004). Transcriptional networks controlling pancreatic development and beta cell function. Diabetologia, 47, 597-613.
126. Sulzbacher, S., Schroeder, I. S., Truong, T. T., & Wobus, A. M. (2009). Activin A-induced differentiation of embryonic stem cells into endoderm and pancreatic progenitors-the influence of differentiation factors and culture conditions. Stem Cell Reviews, 5, 159-173.
127. Soria, B., Roche, E., Berna, G., et al. (2000). Insulin secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes, 49, 157-162.
128. Lumelsky, N., Blondel, O., Laeng, P., et al. (2001). Differentiation of embryonic stem cells to insulin secreting structures similar to pancreatic islets. Science, 292, 1389-1394.
129. Sipione, S., Eshpeter, A., Lyon, J. G., Korbutt, G. S., & Bleackley, R. C. (2004). Insulin expressing cells from differentiated embryonic stem cells are not beta cells. Diabetologia, 47, 499-508.
130. Furth, M. E., & Atala, A. (2009). Stem cell sources to treat diabetes. Journal of Cellular Biochemistry, 106, 507-511.
131. Rolletscheck, A., Kania, G., & Wobus, A. M. (2006). Generation of pancreatic insulin-producing cells from embryonic stem cells-"proof of principle", but questions still unanswered. Diabetologia, 49, 2541-2545.
132. Chakrabarti, S. K., & Mirminra, R. G. (2003). Transcription factors direct the development and function of pancreatic β-cells. Trends in Endocrinology and Metabolism, 14, 78-84.
133. Chen, L. B., Jiang, X. B., & Yang, L. (2004). Differentiation of rat marrow mesenchymal stem cells into pancreatic islet beta-cells. World Journal of Gastroenterology, 10, 3016-3020.
134. Wu, X. H., Liu, C. P., Xu, K. F., et al. (2007). Reversal of hyperglycemia in diabetic rats by portal vein transplantation of islet-like cells generated from bone marrow mesenchymal stem cells. World Journal of Gastroenterology, 13, 3342-3349.
135. Oh, S. H., Muzzonigro, T. M., Bae, S. H., LaPlante, J. M., Hatch, H. M., & Petersen, B. E. (2004). Adult bone marrow-derived cells trans-differentiating into insulin-producing cells for treatment of type I diabetes. Laboratory Investigation, 84, 607-617.
136. Paz, A. H., Salton, G. D., Ayala-Lugo, A., et al. (2010). Betacellulin overexpression in mesenchymal stem cells induces insulin secretion in vitro and ameliorates streptozocin-induced hyperglycemia in rats. Stem Cells and Development. doi: 10. 1089/scd. 2009. 0490.
137. Moriscot, C., De Fraipont, F., Richard, M. J., et al. (2005). Human bone marrow mesenchymal stem cells can express insulin and key transcription factors of the endocrine pancreas developmental pathway upon genetic and/or microenvironmental manipulation in vitro. Stem Cells, 23, 594-604.
138. Li, Y., Zhang, R., Qiao, H., et al. (2007). Generation of insulin-producing cells from PDX-1 gene-modified human mesenchymal stem cells. Journal of Cellular Physiology, 211, 36-44.
139. Lee, R. H., Seo, M. J., Reger, R. L., et al. (2006). Multipotent stromal from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proceedings of the National Academy of Sciences USA, 103, 17438-17443.
140. Sun, Y., Chen, L., Hou, X. G., et al. (2007). Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro. Chinese Medical Journal, 120, 771-776.
141. Karnieli, O., Izhar-Prato, Y., Bulvik, S., & Efrat, S. (2007). Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation. Stem Cells, 25, 2837-2844.
142. Xie, Q. P., Huang, H., Xu, B., et al. (2009). Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microenvironmental manipulation in vitro. Differentiation, 77, 483-491.
143. Zuk, P. A., Zhu, M., Ashjian, P., et al. (2002). Human adipose tissue is a source of multipotent stem cells. Molecular Biology of the Cell, 13, 4279-4295.
144. Timper, K., Seboek, D., Eberhardt, M., et al. (2006). Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells. Biochemical and Biophysical Research Communications, 341, 1135-1140.
145. Trivedi, H. L., Vanikar, A. V., Thakker, A., et al. (2008). Human adipose tissue-derived mesenchymal stem cells combined with hematopoietic stem cell transplantatio synthesize insulin. Transplantation Proceedings, 40, 1135-1139.
146. Pessina, A., Eletti, B., Croera, C., Savalli, N., Diodovich, C., & Gribaldo, L. (2004). Pancreas developing markers expressed on human mononuleated umbilical cord blood cells. Biochemical and Biophysical Research Communications, 323, 315-322.
147. Soria, B. (2001). In vitro differentiation of pancreatic beta-cells. Differentiation, 68, 205-219.
148. Ende, N., Chen, R., & Redid, A. S. (2004). Transplantation of human umbilical cord blood cells improves glycemia and glomerular hypertrophy in type 2 diabetic mice. Biochemical and Biophysical Research Communications, 321, 168-171.
149. Yoshida, S., Ishikawa, F., Kawano, N., et al. (2005). Human cord blood derived cells generate insulin producing cells in vivo. Stem Cells, 23, 1409-1416.
150. Denner, L., Bodenburg, Y., Zhao, J. G., et al. (2007). Directed engineering of umbilical cord blood stem cells to produce C-peptide and insulin. Cellular Proliferation, 40, 367-380.
151. Gao, F., Wu, D. Q., Hu, Y. H., et al. (2008). In vitro cultivation of islet-like cell clusters from human umbilical cord blood-derived mesenchymal stem cells. Translational Research, 151, 293-302.
152. Parekh, V. S., Joglekar, M. V., & Hardikar, A. A. (2009). Differentiation of human umbilical cord blood derived mononuclear cells to endocrine pancreatic lineage. Differentiation, 78, 232-240.
153. Sun, N. Z., & Ji, H. S. (2009). In vitro differentiation of human placenta-derived adherent cells into insulin-producing cells. The Journal of International Medical Research, 37, 400-406.
154. Parolini, O., Alviano, F., Bagnara, G. P., et al. (2008). Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells, 26, 300-311.
155. Chao, K. C., Chao, K. F., Fu, Y. S., & Liu, S. H. (2008). Islet-like clusters derived mesenchymal stem cells in Wharton's jelly of the human Umbilical Cord for transplantation to control type 1 diabetes. PLoS ONE, 3, e1451.
156. Palmer, J. P. (2009). C-peptide in the natural history of type 1 diabetes. Diabetes/Metabolism Research and Reviews, 25, 325-328.
157. Wu, L. F., Wang, N. N., Liu, Y. S., & Wei, X. (2009). Differentiation of Wharton's Jelly primitive stromal cells into insulin-producing cells in comparison with bone marrow mesenchymal stem cells. Tissue Engineering Part A, 15, 2865-2873.
158. Wang, H. S., Shyu, J. F., Shen, W. S., et al. (2010). Transplantation of insulin producing cells derived from umbilical cord stromal mesenchymal stem cells to treat NOD mice. Cell Transplantation. doi: 10. 3727/096368910X522270.
159. Kaneto, H., Matsuoka, T., Kawashima, S., et al. (2009). Role of MafA in pancreatic β-cells. Advanced Drug Delivery Reviews, 61, 489-496.
160. Faustman, D. L., & Davis, M. (2009). The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies. Journal of Molecular Medicine, 87, 1173-1178.
161. Abdi, R., Fiorina, P., Adra, C. N., Atkinson, M., & Sayegh, M. H. (2008). Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes, 57(7), 1759-1767.
162. Eizirik, D. L., Colli, M. L., & Ortiz, F. (2009). The role of inflammation in insulitis and β-cell loss in type 1 diabetes. Nature Reviews Endocrinology, 5, 219-226.
163. Brennand, K., & Melton, D. (2009). Slow and steady is the key to β-cell replication. Journal of Cellular and Molecular Medicine, 13, 472-487.
164. Granger, A., & Kushner, J. A. (2009). Cellular origins of b-cell regeneration: a legacy view of historical controversies. Journal of Internal Medicine, 266, 325-338.